1. Introduction {#s0005}
===============

Potassium bromate (KBrO~3~) is a well-known flour improver that acts as a maturing agent ([@b0165]). It has been in use as a food additive for the past 90 years ([@b0105]). It acts principally in the late dough stage giving strength and elasticity to the dough during the baking process while also promoting the rise of bread. KBrO~3~ is also used in beer making, cheese production and is commonly added to fish paste products ([@b0005]). Additionally, it is used in pharmaceutical and cosmotic industries and is a constituent of cold wave hair solutions ([@b0105]). Moreover, KBrO~3~ can appear as a byproduct in an ozonization of water containing bromide. As a result of KBrO~3~ biotransformation, free radicals generation can cause oxidative damage to essential cellular macromolecules, leading to marked nephrotoxicity and cancer in experimental animals ([@b0040]). International Agency for Research on Cancer (IARC) has classified KBrO~3~ as a possible human carcinogen (group 2B) and its application in food processing was restricted. Indeed, many previous reports has documented that KBrO~3~ can induce multiple organ toxicity in humans and experimental animals ([@b0055], [@b0085], [@b0020]) and that kidney is considered to be the primary target organ of these dangerous compound ([@b0095], [@b0010]). KBrO~3~ is extremely irritating and injurious to tissues especially those of the central nervous system (CNS) and kidneys. The pathological findings included renal tissue damage and haemolysis ([@b0135]). Carcinogenic and mutagenic effects of KBrO~3~ have been also reported in experimental animals ([@b0090]). Several cases of accidental poisoning in children resulting from ingestion of bromate solution and sugar contaminated with bromate were reported as the source of an outbreak of mild poisoning in New Zealand ([@b0130]). Consequently, KBrO~3~ has been banned in several countries including the United Kingdom in 1990, Nigeria in 1993 and Canada in 1994 ([@b0105]). Toxicological studies have convincingly shown that KBrO~3~ affects the nutritional quality of bread as the main vitamins available in bread are degraded ([@b0145]). It is known that KBrO~3~ induces oxidative stress in tissues ([@b0140], [@b0170], [@b0120], [@b0125]) that could be the basis of bromate-induced carcinogenesis ([@b0045]). The present study attempts to assess the effects of oral administration of KBrO~3~ on the lipid profile in plasma, oxidative stress, hepatic and renal histomorphology of Swiss mice using two different doses of KBrO~3~ to compare their effects.

2. Materials and methods {#s0010}
========================

2.1. Animals {#s0015}
------------

Forty five (45) Swiss Webster (SW) mice were obtained from animal house-College of pharmacy-king Saud University and maintained and monitored in a specific pathogen-free environment. All animal procedures were performed in accordance with the standards set forth in the Guidelines for the Care and Use of Experimental Animals issued by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA). The study protocol was approved by the Animal Ethics Committee at King Saud University. All animals were allowed to acclimatize in plastic cages inside a well-ventilated room for one week prior to the experiment. The animals were maintained under standard laboratory conditions (temperature of 23 °C, relative humidity of 60--70% and a 12-h light/dark cycle), fed a diet of standard commercial pellets and given water *ad libitum*.

2.2. KBrO~3~ preparation and dosing schedule {#s0020}
--------------------------------------------

Potassium bromate salt, a product of British drug home limited, Poole England was supplied in its white crystalline form by ASILA chemicals (Saudi Arabia). It was then dissolved in water to prepare the 100 mg/kg dose (0.5 gm/L) and the 200 mg/kg dose (1 gm/L). Animals were divided into 3 groups as follows: Group (I) control group (was given distilled water); Group (II) Low dose KBrO~3~ group (was given 100 mg/kg); Group (III) High dose KBrO~3~ group (was given 200 mg/kg). KBro~3~ was orally administered daily through oral intubation at the two doses of 100 and 200 mg/kg/day for 42 days.

2.3. Sample collection {#s0025}
----------------------

Blood was collected from the heart in heparinized tubes and plasma was obtained for biochemical investigations. Plasma was stored at −80 °C until use. Small pieces of liver and kidneys were removed, cut and put in sterile saline. The pieces were then fixed in 10% neutral buffered formalin and then embedded in paraffin.

2.4. Histological analysis of hepatic and renal tissues {#s0030}
-------------------------------------------------------

The preparation of tissues for histological examination was done as described by [@b0080]; the photomicrographs were observed using the Leitz, DIALUX research microscope at x200. Pathological evaluation in H/E stained tissue sections was done by a pathologist blinded for the experimental regimen.

2.5. Cell blood count (CBC) {#s0035}
---------------------------

Whole blood samples were analyzed with an automatic Vet abc™ Animal Blood Counter (Horiba ABX, Montpellier, France) using the hematology kits specified for that instrument (Horiba ABX, France) according to the manufacturer's instructions.

2.6. Determination of creatinine level in plasma {#s0040}
------------------------------------------------

Plasma samples were analyzed using commercial kits (bioMerieux, Marcy I'Etoile, France) for Creatinine according to the instructions of the manufacturer. Absorbance was measured with an Ultrospec 2000 U/V spectrophotometer (Amersham Pharmacia Biotech, Cambridge, England).

2.7. Lactate dehydrogenase (LDH) {#s0045}
--------------------------------

Lactate dehydrogenase was determined using specified kits LiquiUV Test (Human, Germany) according to the manufacturer's instructions. Briefly, 20 μl of plasma was added to 1000 μl buffer solution (provided by in the kit) then incubated in cuvettes for 5 min at 30 °C. After that, 250 μl of the substrate was mixed with the solution and the absorbance was monitored after 1, 2 and 3 min. The colour development was detected at 340 nm in a spectrophotometer.

2.8. Lipid profile in plasma {#s0050}
----------------------------

LDL, HDL and total cholesterol levels were measured by an enzymatic colorimetric kit (Wako Chemicals USA, Inc.). Briefly, 10 μl of plasma were put into tubes and 1 ml of colour reagent solution was then added. 10 μl of standard solution (provided by in the kit), were put into tubes and 1 ml of colour reagent solution was then added. The solution was mixed well and incubated at 37 °C for 5 min. The colour development was detected at 500 nm in a spectrophotometer.

2.9. Glutathione (GSH) assay {#s0055}
----------------------------

Glutathione content was determined according to the procedure of [@b0035] with some modification. Briefly, 0.20 ml of tissue supernatant was mixed with 1.5 ml precipitating solution containing 1.67% glacial metaphosphoric acid, 0.20% Na-EDTA and 30% NaCl. The mixture was allowed to stand for 5 min at room temperature and centrifuged 1000*g* for 5 min. One ml clear supernatant was mixed with 4 ml 0.30 M Na~2~HPO~4~ and 0.50 ml DTNB reagent (40 mg 5, 5′dithiobis-(2-nitrobenzoic acid dissolved in 1% sodium citrate). A blank was similarly prepared in which 0.20 ml water was used instead of the brain supernatant. The absorbance of the color was measured at 412 nm in a spectrophotometer.

2.10. Statistical analysis {#s0060}
--------------------------

Prior to further statistical analysis, the data were tested for normality using the Anderson-Darling test, as well as for homogeneity variances. The data was normally distributed and is expressed as the mean ± standard error of the mean (SEM). Significant differences among the groups were analysed by one- or two-way ANOVA followed by Bonferroni's test for multiple comparisons using PRISM statistical software (GraphPad Software). The data was also reanalysed by one- or two-way ANOVA followed by Tukey's post-test using SPSS software, version 17. Differences were considered statistically significant at P \< 0.05.

3. Results {#s0065}
==========

3.1. Decreased WBCs, RBCs and platelets count after KBrO~3~ intake {#s0070}
------------------------------------------------------------------

WBCs count was significantly decreased in both of KBrO~3~ treated groups. As shown in [Table 1](#t0005){ref-type="table"}, the low dose of KBrO~3~ was associated with a lower number of WBCs in comparison to the control group. Additionally, the high dose of KBrO~3~ was accompanied with a much more decrease in the WBCs count in comparison to either the control or the low dose group. RBCs count was also decreased in the low dose KBrO~3~ group in comparison to the control group. Similarly, the decrease in RBCs count was higher in the high dose KBrO~3~ group in comparison to both the low dose and the control one. Platelets count was having a similar pattern of decrease in both of KBrO~3~ treated groups. A significantly decreased Platelets count was detected in the low dose KBrO~3~ group. On the other hand, the high dose KBrO~3~ group has showed a lower platelets count in comparison to either the control group or the low dose KBrO~3~ group.Table 1Effect of KBrO~3~ treatment on the RBCs, WBCs and platelets count RBCs, WBCs and platelets count were measured in the three groups of mice, and the results are presented as the means ± SEM (n = 10), ^\*^P \< 0.05 for low dose KBrO~3~ group vs. control; ^\#^P \< 0.05 for high dose KBrO~3~ group vs. control.Mean total leukocyte count (×10^9^/L)Mean total reticulocyte count (×10^9^/L)Mean platelet count (×10^9^/L)Control11.3 ± 0.628.3352 ± 0.13200875 ± 38KBrO~3~ (100 mg/dl)10.0 ± 0.58^\*^7.2550 ± 0.3294^\*^423 ± 42^\*^KBrO~3~ (200 mg/dl)9.5 ± 0.93^\#^7.1375 ± 0.4019^\#^405 ± 63^\#^

3.2. Altered lipid profile in plasma of KBrO~3~ treated mice {#s0075}
------------------------------------------------------------

Disturbance in lipid profile in plasma is considered as an indicator for many physiological disorders. LDL, HDL and cholesterol levels in plasma samples of the three experimental groups were investigated. Both of the low and the high doses of KBrO~3~ were accompanied with a significant reduction in the plasma concentrations of HDL ([Fig.1](#f0005){ref-type="fig"}a). Conversely, the plasma level of LDL was increased in both of the low and the high dose KBrO~3~ groups. A significant increase was detected in the high dose KBrO~3~ group in comparison to the control group ([Fig.1](#f0005){ref-type="fig"}b). Nevertheless, the change in the plasma level of cholesterol ([Fig.1](#f0005){ref-type="fig"}c) in both of KBrO~3~ groups was not significant in comparison to the control group.Fig. 1Effect of KBrO~3~ on the lipid profile in plasma samples of treated mice using two different doses of KBrO~3~. (a) Plasma level of high density lipoprotein, (b) Plasma level of low density lipoprotein, (c) Plasma level of cholesterol. The data are the mean ± SEM for 10 mice per group. ^\*^P \< 0.05 for low dose KBrO~3~ treated group vs. control group; ^\#^P \< 0.05 for high dose KBrO~3~treated group vs. control group; ^+^P \< 0.05 for high dose KBrO~3~ treated group vs. low dose KBrO~3~ treated group.

3.3. KBrO~3~ treatment was associated with an increased plasma level of LDH {#s0080}
---------------------------------------------------------------------------

LDH is often used as a marker of tissue breakdown and can function as an indicator for liver toxicity. [Fig. 2](#f0010){ref-type="fig"} illustrates that both groups of the high and the low doses of potassium bromate were associated with a significant increase in the plasma level of LDH in comparison to the control group. However, the high dose of potassium bromate was accompanied with a much more increase in the LDH level in comparison to either the control or the low dose group.Fig. 2Effect of KBrO~3~ on the lactate dehydrogenase level in plasma samples of treated mice. The data are the mean ± SEM for 10 mice per group. ^\*^P \< 0.05 for low dose KBrO~3~ treated group vs. control group; ^\#^P \< 0.05 for high dose KBrO~3~treated group vs. control group; ^+^P \< 0.05 for high dose KBrO~3~ treated group vs. low dose KBrO~3~ treated group.

3.4. Impaired hepatic and renal histology concomitant with increased plasma Creatinine in both KBrO~3~ groups {#s0085}
-------------------------------------------------------------------------------------------------------------

As a result of KBrO~3~ treatment, hepatic tissue sections of KBrO~3~ treated mice have showed a congestion of central vein with a relative increase in Kuppfer cells (KCs) in comparison to the control group ([Fig. 3](#f0015){ref-type="fig"}). Renal tissue of KBrO~3~ treated group of mice was largely affected in comparison to the control group. Hemorrhage was seen in both KBrO~3~ treated groups. Dilated blood vessels were seen in the high dose KBrO~3~ treated group ([Fig. 4](#f0020){ref-type="fig"}). To confirm these findings, Creatinine level in plasma, which is considered as an important indicator for kidney function, was determined. As illustrated in [Fig. 5](#f0025){ref-type="fig"}, a significant increase in the plasma level of Creatinine in both of KBrO~3~ treated groups was detected. The low dose group had a higher plasma level of Creatinine in comparison to the control. The high dose group has exhibited a much more increase in the plasma level of Creatinine in comparison to both the control and the low dose one.Fig. 3Effect of KBrO~3~ on the histology of liver. Sections of liver showing central vein (CV), congested central vein (CCV), hepatic sinusoid (S), vacuoles (V), hepatic cell (HC), Kuppfer cell (KC). (A, B) control group, (C, D) potassium bromate 100 mg/kg group, (E, F) potassium bromate 200 mg/kg group. Scale bar = 400 μm in A, C, E and 50 μm in B, D, F.Fig. 4Effect of KBrO~3~ on the histology of kidney. sections in the kidney showing the kidney tubules (arrow head), Bowman's capsule (arrow),Hemorrhage (H) and dilated blood vessels (DV). (A, B) control group, (C, D) potassium bromate 100 mg/kg group, (E, F) potassium bromate200 mg/kg group. (H & E stain, Scale bar = 200 μm in A, C, E and 50 μm in B, D, F).Fig. 5Effect of KBrO~3~ on the plasma level of Creatinine. The data are the mean ± SEM for 10 mice per group. ^\*^P \< 0.05 for low dose KBrO~3~ treated group vs. control group; ^\#^P \< 0.05 for high dose KBrO~3~ treated group vs. control group; ^+^P \< 0.05 for high dose KBrO~3~ treated group vs. low dose KBrO~3~ treated group.

3.5. Decreased glutathione level in both renal and hepatic tissues of KBrO~3~ treated mice {#s0090}
------------------------------------------------------------------------------------------

Reduced glutathione (GSH) is an important antioxidant that plays a crucial role in nearly all living organisms. KBrO~3~ treatment had a negative impact on both the renal and the hepatic level of this important molecule. In the low dose KBrO~3~ group, both of the renal and the hepatic levels of GSH were significantly decreased in comparison to that of the control group. At the same time, a significant reduction in the level of this crucial molecule was also monitored in both the renal and hepatic homogenates of the high dose KBrO~3~ group in comparison to either the control group or the low dose KBrO~3~ group ([Fig. 6](#f0030){ref-type="fig"}).Fig. 6Effect of KBrO~3~ on the hepatic and renal level of GSH. The data are the mean ± SEM for 10 mice per group. ^\*^P \< 0.05 for low dose KBrO~3~ treated group vs. control group; ^\#^P \< 0.05 for high dose KBrO~3~treated group vs. control group; ^+^P \< 0.05 for high dose KBrO~3~ treated group vs. low dose KBrO~3~ treated group.

4. Discussion {#s0095}
=============

Potassium bromate (KBrO~3~) is widely used as improving additive for bread making ([@b0020]) and marketed as a neutralizer in home permanent cold wave hair kits that caused several cases of accidental poisoning in children resulting from the ingestion of this solution ([@b0130]). Due to its hazardous effects, it has been forbidden in various countries ([@b0105]). The current study was designed to investigate some of the biochemical changes induced by KBrO~3~ intake in Swiss Mice. We have observed that the total reticulocyte, leukocyte and platelet counts in the plasma samples of both KBrO~3~ treated groups have been significantly decreased in comparison to the control group. These reductions in the leukocyte and platelet counts could be due to the DNA strand breakage in these cells induced by the oxidative stress associated with KBrO~3~, ([@b0040], [@b0150], [@b0125], [@b0160]). Furthermore, there could have been bone marrow suppression with selective megakaryocytic depression ([@b0065]). So, the reductions in the RBCs, WBCs and platelets could imply selective systemic toxicity effect by KBrO~3~. Lipid profile represents an important indicator of several pathological conditions. The most common metabolic contributor to the coronary artery disease is the atherogenic lipoprotein profile, characterized by an increased LDL level and a deficiency of HDL level ([@b0155]). Many studies have reported that increased level of LDL is associated with higher risk of atherosclerosis while elevated level of HDL is linked to reduced occurrences of cardiovascular disorders ([@b0060], [@b0110]). In the current study, the level of plasma HDL decreased with both doses of KBrO~3~ leading to elevated atherogenic index which can be used to predict the risk for development of cardiovascular disorders. Therefore, the high ratio of LDL to HDL, caused by KBrO~3~, may implicate increased tendency for the development of atherosclerosis. LDH is considered as a liver toxicity indicator and the increased LDH level in KBrO~3~ groups that has been observed in the current study is in accordance with previous reports ([@b0015]). In another study, KBrO~3~ induced chromosomal aberrations (CA) and decreased both the cell proliferation index (PI) and the mitotic index (MI) of human peripheral lymphocytes in vitro ([@b0070]). Histological observation of hepatic tissue sections has confirmed the liver pathology due to KBrO~3~. Previous studies have illustrated that KBrO~3~ treatment in wister rats have hepatotoxic effects ([@b0115]). KBrO~3~-mediated renal injury in Wistar rats was also recorded before ([@b0075]). In the current study, histological findings in renal tissue of KBrO~3~ treated groups were supported by previous reports ([@b0095]). A dose-dependent increase in the numbers of eosinophilic droplets within the proximal tubule epithelium was observed in male F344 rats exposed to 20,100, 200, or 400 mg/L KBrO~3~ for 12 weeks ([@b0175]). [@b0090] reported similar lesions in proximal renal tubules of male F344 rats following 13 weeks exposure of 500 mg/L KBrO~3~. In addition to that, [@b0050] have reported similar results in the same animal model. So the results in the current study agree very well with the results of these sub chronic studies. Elevated levels of Creatinine in plasma were observed confirming previous reports that KBrO~3~ ingestion causes acute kidney damage ([@b0095], [@b0030]). Reduced glutathione is an important antioxidant molecule that can be used by many organs, including kidney and liver, to withstand the induced oxidative stress. Previous studies have illustrated that KBrO~3~ can decrease the tissue content of this molecule ([@b0040], [@b0125]). In agreement with these previous results, the current study illustrated that renal and hepatic levels of GSH have been reduced after KBrO~3~ treatment with more reduction in the high dose KBrO~3~ group in comparison to the low dose one. A similar effect has been observed in our previous study in brain tissue ([@b0025]) Taken together, our data reveals that KBrO~3~ has several harmful effects on the biochemical and histological levels and therefore, its consumption should be prohibited.

5. Conclusions {#s0100}
==============

KBrO~3~ treatment in Swiss Mice has several consequences like disturbance in blood biochemistry, renal and hepatic histopathology and decreased antioxidant capacity. These dangerous effects should stop its use in human being.
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